Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Zurich
About this trial
Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
CT SCAN for pulmonary nodule detection/follow up
CT SCAN for pneumonia detection/follow up
Disqualifiers
under 18
BMI over 30
Trial design
Design model
Parallel
Treatments tested in this trial
Computed Tomography
RadiationComputed Tomography CHEST
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: Low DoseOther 1 intervention
Group B: Ultra Low DoseOther 1 intervention
Trial outcomes
Primary outcomes
1
Dose Reduction by new scanner
mSv per exam will be recorded. This value will be put in correlation to weight (Kg), height (cm) and BMI.
Time frame
through study completion, an average of 1 year2
stable Image Quality in reduced dose scans
Recorded values compared in 2 populations-different contrast agents by using qualitative\&quantitative methods Qualitative:diagnostic certainty, assessability of lung structure/lesions,diagnostic reliability, Quantitative:Assessment of tissue composition,diagnostic performance measurements Attenuation/sealing measurement (HU), signal-to-noise ratio (SNR), contrast-to-noise ratio ,size dimensions of lung structure/lesion in three dimensions in millimeters Tissue composition assessment diagnostic performance measurements (sensitivity, specificity, accuracy) diagnostic confidence: 1-4 Theses measurements will be put in correlation to the scan dose (mSv) per patient, forming two groups with matched BMI (kg/m\^2)
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov